Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries

IMPORTANCE: Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes in a real-world population are not yet characterized. OBJECTIVE: We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Bird, Steven T., Tian, Fang, Flowers, Natasha, Przepiorka, Donna, Wang, Rongrong, Jung, Tae-Hyun, Kessler, Zebulin, Woods, Corinne, Kim, Bo, Miller, Barry W., Wernecke, Michael, Kim, Clara, McKean, Stephen, Gelperin, Kate, MaCurdy, Thomas E., Kelman, Jeffrey A., Graham, David J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990831/
https://ncbi.nlm.nih.gov/pubmed/31855259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.3994
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados